A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Status:
Active, not recruiting
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a new drug called IPI-145 in combination with the standard
drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic
lymphocytic leukemia (CLL).